Tilray Brands (NASDAQ:TLRY – Get Free Report) and Liquidia (NASDAQ:LQDA – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Institutional and Insider Ownership
9.3% of Tilray Brands shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 1.6% of Tilray Brands shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Tilray Brands and Liquidia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tilray Brands | -16.91% | -10.39% | -7.38% |
| Liquidia | -15.15% | 264.65% | 44.19% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tilray Brands | $915.45 million | 0.31 | -$121.40 million | ($1.40) | -1.35 |
| Liquidia | $158.32 million | 30.98 | -$68.92 million | ($1.23) | -44.25 |
Liquidia has lower revenue, but higher earnings than Tilray Brands. Liquidia is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and price targets for Tilray Brands and Liquidia, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tilray Brands | 2 | 2 | 3 | 1 | 2.38 |
| Liquidia | 1 | 5 | 5 | 1 | 2.50 |
Tilray Brands currently has a consensus price target of $5.90, indicating a potential upside of 212.17%. Liquidia has a consensus price target of $75.23, indicating a potential upside of 38.22%. Given Tilray Brands’ higher possible upside, analysts clearly believe Tilray Brands is more favorable than Liquidia.
Risk and Volatility
Tilray Brands has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Summary
Liquidia beats Tilray Brands on 10 of the 14 factors compared between the two stocks.
About Tilray Brands
Tilray Brands is a global cannabis and consumer packaged goods company. Its cannabis business produces and sells medical and adult-use products, including dried flower, oils, extracts and edibles, under brands such as Good Supply, Solei, Redecan and Broken Coast. The company serves customers in Canada, the United States and international markets. Its activities include medical cannabis distribution in countries where permitted, as well as cannabis and hemp-related products in North America, subject to local regulations.
About Liquidia
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
